These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30029060)

  • 81. Reaction of Amyloid-β Peptide Antibody with Different Infectious Agents Involved in Alzheimer's Disease.
    Vojdani A; Vojdani E; Saidara E; Kharrazian D
    J Alzheimers Dis; 2018; 63(2):847-860. PubMed ID: 29689721
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Yeast expressed foldable quadrivalent Aβ15 elicited strong immune response against Aβ without Aβ-specific T cell response in wild C57BL/6 mice.
    Tan L; Wang H; Tan X; Zou J; Yao Z
    Hum Vaccin Immunother; 2012 Aug; 8(8):1090-8. PubMed ID: 22854673
    [TBL] [Abstract][Full Text] [Related]  

  • 83. DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation.
    Lambracht-Washington D; Qu BX; Fu M; Anderson LD; Stüve O; Eagar TN; Rosenberg RN
    Cell Mol Neurobiol; 2011 Aug; 31(6):867-74. PubMed ID: 21625960
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Intramembranous fragment of amyloid-beta: A potential immunogen for Alzheimer's disease immunotherapy.
    Zhang S; Wu L; Liu F; Huang B; Huang D; Yang L; Peng Z
    Neurochem Res; 2009 Nov; 34(11):1889-95. PubMed ID: 19347579
    [TBL] [Abstract][Full Text] [Related]  

  • 85. A Therapeutic Nanovaccine that Generates Anti-Amyloid Antibodies and Amyloid-specific Regulatory T Cells for Alzheimer's Disease.
    Jung M; Lee S; Park S; Hong J; Kim C; Cho I; Sohn HS; Kim K; Park IW; Yoon S; Kwon S; Shin J; Lee D; Kang M; Go S; Moon S; Chung Y; Kim Y; Kim BS
    Adv Mater; 2023 Jan; 35(3):e2207719. PubMed ID: 36329674
    [TBL] [Abstract][Full Text] [Related]  

  • 86. DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model.
    Lambracht-Washington D; Qu BX; Fu M; Eagar TN; Stüve O; Rosenberg RN
    JAMA; 2009 Oct; 302(16):1796-802. PubMed ID: 19861672
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice.
    Rasool S; Albay R; Martinez-Coria H; Breydo L; Wu J; Milton S; Misra S; Tran A; Pensalfini A; Laferla F; Kayed R; Glabe CG
    Mol Neurodegener; 2012 Aug; 7():37. PubMed ID: 22866920
    [TBL] [Abstract][Full Text] [Related]  

  • 88. CD4 T cells in immunity and immunotherapy of Alzheimer's disease.
    Monsonego A; Nemirovsky A; Harpaz I
    Immunology; 2013 Aug; 139(4):438-46. PubMed ID: 23534386
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Plant-based vaccines for Alzheimer's disease.
    Ishiura S; Yoshida T
    Proc Jpn Acad Ser B Phys Biol Sci; 2019; 95(6):290-294. PubMed ID: 31189781
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates.
    Davtyan H; Ghochikyan A; Petrushina I; Hovakimyan A; Davtyan A; Cribbs DH; Agadjanyan MG
    Alzheimers Dement; 2014 May; 10(3):271-83. PubMed ID: 24560029
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Generation of auto-antibodies towards Alzheimer's disease vaccination.
    Frenkel D; Kariv N; Solomon B
    Vaccine; 2001 Mar; 19(17-19):2615-9. PubMed ID: 11257400
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies.
    Tabira T
    Tohoku J Exp Med; 2010 Feb; 220(2):95-106. PubMed ID: 20139660
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Effects of a 15-amino-acid isoform of amyloid- β expressed by silkworm pupae on B6C3-Tg Alzheimer's disease transgenic mice.
    Li S; Jin Y; Wang C; Chen J; Yu W; Jin Y; Lv Z
    J Biotechnol; 2019 Apr; 296():83-92. PubMed ID: 30898688
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Advances in the development of vaccines for Alzheimer's disease.
    Lambracht-Washington D; Rosenberg RN
    Discov Med; 2013 May; 15(84):319-26. PubMed ID: 23725605
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Immunodominant epitope and properties of pyroglutamate-modified Abeta-specific antibodies produced in rabbits.
    Acero G; Manoutcharian K; Vasilevko V; Munguia ME; Govezensky T; Coronas G; Luz-Madrigal A; Cribbs DH; Gevorkian G
    J Neuroimmunol; 2009 Aug; 213(1-2):39-46. PubMed ID: 19545911
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Transgenic rice expressing amyloid β-peptide for oral immunization.
    Yoshida T; Kimura E; Koike S; Nojima J; Futai E; Sasagawa N; Watanabe Y; Ishiura S
    Int J Biol Sci; 2011 Mar; 7(3):301-7. PubMed ID: 21448341
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Simplified β-amyloid peptides for safer Alzheimer's vaccines development.
    Verdoliva A; Rivieccio V; Rossi M
    Hum Vaccin; 2010 Nov; 6(11):936-47. PubMed ID: 20980800
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A modification-specific peptide-based immunization approach using CRM197 carrier protein:
    Vingtdeux V; Zhao H; Chandakkar P; Acker CM; Davies P; Marambaud P
    Mol Med; 2017 Jan; 22():841-849. PubMed ID: 27900387
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy.
    Movsesyan N; Ghochikyan A; Mkrtichyan M; Petrushina I; Davtyan H; Olkhanud PB; Head E; Biragyn A; Cribbs DH; Agadjanyan MG
    PLoS One; 2008 May; 3(5):e2124. PubMed ID: 18461171
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Immunotherapy for Alzheimer's disease.
    Dodel RC; Hampel H; Du Y
    Lancet Neurol; 2003 Apr; 2(4):215-20. PubMed ID: 12849209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.